Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Alkermes Plc

ALKS
Current price
23.85 USD +0.2 USD (+0.85%)
Last closed 23.76 USD
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Exchange NASDAQ
Capitalization 4 079 995 904 USD
Yield for 12 month -17.76 %
1Y
3Y
5Y
10Y
15Y
ALKS
21.11.2021 - 28.11.2021

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland. Address: Connaught House, Dublin, Ireland, D04 C5Y6

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

35.91 USD

P/E ratio

7.9804

Dividend Yield

Current Year

+1 663 405 000 USD

Last Year

+1 111 795 000 USD

Current Quarter

+377 475 000 USD

Last Quarter

+380 938 000 USD

Current Year

+1 374 679 000 USD

Last Year

+893 687 000 USD

Current Quarter

+298 353 000 USD

Last Quarter

+319 429 000 USD

Key Figures ALKS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA 495 048 992 USD
Operating Margin TTM 14.47 %
PE Ratio 7.9804
Return On Assets TTM 12.81 %
PEG Ratio -1057.29
Return On Equity TTM 46.22 %
Wall Street Target Price 35.91 USD
Revenue TTM 1 663 405 056 USD
Book Value 7.2 USD
Revenue Per Share TTM 10.01 USD
Dividend Share
Quarterly Revenue Growth YOY 23.9 %
Dividend Yield
Gross Profit TTM 893 687 000 USD
Earnings Share 3.06 USD
Diluted Eps TTM 3.06 USD
Most Recent Quarter IV 2023
Quarterly Earnings Growth YOY
Profit Margin 21.39 %

Dividend Analytics ALKS

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History ALKS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 2:1
Payout Ratio
Last Split Date 15.05.2000
Dividend Date

Stock Valuation ALKS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE 7.9804
Forward PE 9.5511
Enterprise Value Revenue 2.2115
Price Sales TTM 2.4528
Enterprise Value EBITDA 7.0815
Price Book MRQ 3.3924

Financials ALKS

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators ALKS

For 52 weeks

22.01 USD 33.71 USD
50 Day MA 28.02 USD
Shares Short Prior Month 14 084 612
200 Day MA 27.86 USD
Short Ratio 6.93
Shares Short 14 335 888
Short Percent 9.79 %

Dynamics of changes in the value of assets

Stocks


MSFT

MSFT

399.12 USD Microsoft Corporation -4.91 (-1.22%)
Detailed analytics

ETF funds


M

MDAXEX

207.85 CHF iShares MDAX UCITS ETF (DE) 0 (0%)
Detailed analytics

Metals


Gold

2175.88 USD Gold +5.94 (+0.27%)
Detailed analytics